Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
michael.desborough@linacre.ox.ac.uk
michael.desborough@ouh.nhs.uk

Address
Department of Clinical Haematology, Churchill Hospital, Oxford, OX3 9DU

Pronouns
He/Him

Research groups

Desborough Group: Platelet disorders and transfusion

Colleges

Linacre College

Michael Desborough

BMedSci(Hons), MB ChB, FRCP, FRCPath, DPhil

Consultant Haematologist & Associate Professor of Haematology

The overarching aim of the research conducted by my group is to develop and trial new treatments for platelet disorders and finding alternatives to platelet transfusion.

This includes trials of reversing antiplatelet drugs in intracerebral haemorrhage
Optimising treatment of fetal and neonatal alloimmune thrombocytopenia (FNAIT)
Clinical trials in transfusion medicine and immunohaematology [thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenia (ITP), warm autoimmune haemolytic anaemia (wAIHA), cold agglutinin disease (CAD)]
Developing the evidence base for platelet transfusion and alternatives to transfusion

Key publications

Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.

Desborough MJR. et al, (2023), Lancet Neurol, 22, 557 - 567

Drug-induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data.

Schofield J. et al, (2023), Br J Haematol, 201, 766 - 773

Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders.

Thomas W. et al, (2021), J Thromb Haemost, 19, 2738 - 2743

Real-world experience with caplacizumab in the management of acute TTP.

Dutt T. et al, (2021), Blood, 137, 1731 - 1740

Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials.

Odutayo A. et al, (2017), Lancet Gastroenterol Hepatol, 2, 354 - 360

Recent publications

ntifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders.

Champaneria R. et al, (2026), Cochrane Database Syst Rev, 2

Recombinant von Willebrand Factor (vonicog alfa) reduces platelet inhibition caused by antiplatelet drugs and has potential as an acute haemostatic agent.

Desborough MJR. et al, (2026), Haematologica

Can drug-induced platelet dysfunction be reversed?

Maynard S. et al, (2026), Res Pract Thromb Haemost, 10

Baseline serum ferritin predicts myocardial iron uptake following intravenous iron therapy - a hypothesis-generating study.

Nunez J. et al, (2025), Eur J Heart Fail, 27, 2352 - 2356

BO matching for platelet transfusions for prevention or treatment of bleeding: A systematic review with meta-analysis.

Cain L. et al, (2025), Transfus Med Rev

More publications

ORCID

0000-0002-1951-5616